Even with significant advances in operative skills and adjuvant therapies, the overall survival of patients suffering with head and neck squamous cancers (HNSCC) is unsatisfactory. Accordingly, no clinically useful prognostic biomarkers have been found yet for HNSCC. Many studies analysed the expression of potential markers in tumour tissues compared to adjacent tissues. Nevertheless, due to the sharing of the same microenvironment, adjacent tissues show molecular similarity to tumour tissues. Thus, gene expression patterns of 94 HNSCC tumorous tissues were compared with 31 adjacent tissues and with 10 tonsillectomy specimens of non-cancer individuals. The genes analysed at RNA level using quantitative RT-PCR and correlated with clinico-pathological conditions were as follows: EGF, EGFR, MKI67, BCL2, BAX, FOS, JUN, TP53, VEGF, FLT1, MMP2, MMP9, MT1A and MT2A. The elevated MT2A, BAX, EGF and JUN expression was associated with the influence of tumour cells on the rearrangement of healthy tissues, as well as a significant shift in the BAX/BCL2 ratio. Our investigation also indicated that adjacent tissues play an important role in cancerogenesis by releasing several tumour-supporting factors such as EGF. A gradual increase in the metallothionein expression, from the lowest one in tonsillectomy samples to the highest ones in tumour samples, suggests that MT expression might be tissue reaction to the presence of tumour cells. The results of this study confirmed the significance of metallothionein in tumori-genesis and gave evidences for its use as a potential HNSCC biomarker. Furthermore, this study highlighted the importance of histologically normal tumour-adjacent tissue in prediction of HNSCC progress.

Central European Institute of Technology Brno University of Technology Technicka 3058 10 CZ 616 00 Brno Czech Republic

Department of Chemistry and Biochemistry Mendel University in Brno Zemedelska 1 CZ 613 00 Brno Czech Republic

Department of Otorhinolaryngology and Head and Neck Surgery St Anne's Faculty Hospital Pekarska 53 CZ 656 91 Brno Czech Republic

Department of Pathological Physiology Faculty of Medicine Masaryk University Kamenice 5 CZ 625 00 Brno Czech Republic

Department of Physiology Faculty of Medicine Masaryk University Kamenice 5 CZ 625 00 Brno Czech Republic

Erratum v

Tumour Biol. 2021;43(1):71. doi: 10.3233/TUB-219001. PubMed

Zobrazit více v PubMed

Mol Cancer. 2014 Mar 05;13:46 PubMed

Cell Tissue Res. 2013 May;352(2):341-9 PubMed

Front Biosci (Landmark Ed). 2010 Jan 01;15:180-94 PubMed

Oral Oncol. 2006 May;42(5):533-9 PubMed

Exp Cell Res. 2012 Aug 1;318(13):1517-27 PubMed

BMC Cancer. 2005 May 13;5:45 PubMed

Oncogene. 2010 Aug 5;29(31):4449-59 PubMed

Biometals. 1993 Summer;6(2):71-6 PubMed

Am J Otolaryngol. 2011 Mar-Apr;32(2):141-6 PubMed

J Exp Ther Oncol. 2010;8(3):211-21 PubMed

Int J Cancer. 2007 Dec 1;121(11):2373-80 PubMed

FASEB J. 1997 Oct;11(12):947-53 PubMed

Oral Oncol. 2009 Oct;45(10):920-5 PubMed

Br J Cancer. 2014 May 27;110(11):2677-87 PubMed

Int J Exp Pathol. 2005 Dec;86(6):347-63 PubMed

Cancers (Basel). 2014 Jan 27;6(1):240-96 PubMed

Curr Opin Pharmacol. 2009 Aug;9(4):389-95 PubMed

Exp Biol Med (Maywood). 2005 Jan;230(1):75-81 PubMed

Breast. 2012 Jun;21(3):366-73 PubMed

Cancer. 1994 Jul 15;74(2):565-72 PubMed

Cancer Biomark. 2010;9(1-6):325-39 PubMed

Head Neck. 2008 Oct;30(10):1273-83 PubMed

Cancer Res. 2005 Jul 1;65(13):5554-60 PubMed

Cancer Cell. 2009 Mar 3;15(3):232-9 PubMed

Cancer Res. 1993 Aug 1;53(15):3579-84 PubMed

J Clin Oncol. 2006 Jun 10;24(17):2666-72 PubMed

Am J Reprod Immunol. 2013 Sep;70(3):253-61 PubMed

Nat Rev Cancer. 2014 Sep;14(9):632-41 PubMed

BJU Int. 2013 Jun;111(8):1245-52 PubMed

FEBS Lett. 1998 Dec 4;440(3):419-24 PubMed

Invest Ophthalmol Vis Sci. 1993 Jun;34(7):2348-51 PubMed

Mediators Inflamm. 2009;2009:101659 PubMed

Acta Oncol. 2014 May;53(5):637-45 PubMed

Oncogene. 2009 Jul 30;28(30):2723-37 PubMed

Int J Cancer. 1999 Dec 22;84(6):573-9 PubMed

Development. 1992 May;115(1):49-58 PubMed

Cancer Res. 2002 Dec 15;62(24):7350-6 PubMed

Oral Oncol. 2014 Mar;50(3):168-77 PubMed

Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2956-60 PubMed

Oncogene. 2007 Mar 1;26(10):1459-67 PubMed

J Cancer. 2013;4(1):66-83 PubMed

Histochem Cell Biol. 2008 Dec;130(6):1079-90 PubMed

Cancer Cell. 2009 Mar 3;15(3):220-31 PubMed

Neuro Endocrinol Lett. 2005 Oct;26(5):567-74 PubMed

Int J Mol Sci. 2013 Mar 15;14(3):6044-66 PubMed

Clin Cancer Res. 1998 Jan;4(1):13-20 PubMed

PLoS One. 2014 Jan 08;9(1):e85346 PubMed

Oral Oncol. 1999 May;35(3):227-33 PubMed

Cancer. 2002 Feb 1;94(3):713-22 PubMed

Mol Cancer Res. 2009 Aug;7(8):1189-96 PubMed

Mol Cancer Ther. 2011 Nov;10(11):2124-34 PubMed

Arch Otolaryngol Head Neck Surg. 1992 May;118(5):483-5 PubMed

Am J Pathol. 2007 Oct;171(4):1189-98 PubMed

Free Radic Biol Med. 1993 Mar;14(3):325-37 PubMed

Am J Pathol. 2011 Jun;178(6):2857-65 PubMed

Cell Cycle. 2013 May 1;12(9):1371-84 PubMed

Cancer Gene Ther. 2003 Nov;10(11):823-32 PubMed

Oncogene. 2007 Nov 8;26(51):7194-203 PubMed

Biochim Biophys Acta. 2005 May 25;1755(1):37-69 PubMed

Pathol Res Pract. 1999;195(12):809-14 PubMed

Cell Death Differ. 2003 Mar;10(3):323-34 PubMed

Evaluation of EGFR as a prognostic and diagnostic marker for head and neck squamous cell carcinoma patients

Effect of HPV on tumor expression levels of the most commonly used markers in HNSCC